Results 111 to 120 of about 243,161 (291)

Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: A retrospective cohort study.

PLoS Medicine
BackgroundThe U.S. Food and Drug Administration (FDA) has the authority to require that sponsors conduct pediatric studies for certain new drugs under the Pediatric Research Equity Act (PREA). Here, we evaluate the characteristics and completion of these
Rylee McGonigle, Huseyin Naci, Maximilian Siebert, Michelle Ouvina, Alba Gutiérrez-Sacristán, Anita K Wagner, Florence T Bourgeois   +6 more
doaj   +1 more source

Research of ddi based on multi-label conditional random field

BIO Web of Conferences, 2017
The detection of drug name and drug-drug interaction(DDI) is considered as a sequence labeling task in this paper. We present the multi-label CRF method to complete it.
Yu Yangzhi, Deng Hongtao, Zhu Xun
doaj   +1 more source

Effects of IGFBP4 deficiency on human preadipocyte proliferation and differentiation through the IGF1R/AKT pathway

FEBS Open Bio, EarlyView.
IGFBP4 knockdown (KD) impairs preadipocyte proliferation and is associated with IGF1R protein downregulation and attenuated AKT phosphorylation. The mechanisms by which IGFBP4 KD influences the IGF1R/AKT signaling pathway involve newly synthesized proteins and lysosomal degradation pathways. Created in BioRender.
Yujia Guo, Sandy Richter, Christoph Bach, Wieland Kiess, Anna Kirstein, Diana Le Duc, Antje Garten   +6 more
wiley   +1 more source

THE ECONOMICS OF LABELING: AN OVERVIEW OF ISSUES FOR HEALTH AND ENVIRONMENTAL DISCLOSURE

During the last two decades, product labeling has become an increasingly used policy tool, particularly with respect to the provision of health and environmental information.
Teisl, Mario F., Roe, Brian E.
core  

Use of Titration as a Therapeutic Individualization Strategy: An Analysis of Food and Drug Administration–Approved Drugs

Clinical and Translational Science, 2019
Selecting a dose regimen that is both safe and effective for patients is one of the most critical elements of a successful drug development program. Titrating the dose regimen of a drug based on patient response may help to identify safe and effective ...
Robert N. Schuck, Michael Pacanowski, Sarah Kim, Rajanikanth Madabushi, Issam Zineh   +4 more
doaj   +1 more source

From energy provision to protein synthesis: Tunnelling nanotubes as mediators of intercellular metabolic cooperation in cancer

FEBS Open Bio, EarlyView.
The cytoskeleton‐mediated transport of mitochondria via tunnelling nanotubes restores respiration, increases ATP production, rescues cells from apoptosis, activates the AKT/mTOR signalling pathway, promotes cell migration and invasiveness, contributes to cancer progression and treatment resistance.
Stanislava Martínková, Jan Trnka
wiley   +1 more source

MagmaFlow: A desktop platform for artificial intelligence‐driven expression analysis

FEBS Open Bio, EarlyView.
MagmaFlow is a free, no‐code platform for gene expression analysis. It generates interactive volcano plots, links genes to literature, pathways, and diseases, prioritizes candidates using millions of publications, identifies affected biological processes, builds network diagrams, and exports publication‐ready figures and reports for macOS and Windows ...
Carlos E. Buss, Ao Li, Eduardo H. Gilglioni, Mayank Bansal, Sumeet Pal Singh, Latifa Bakiri, Alessandra K. Cardozo, Esteban N. Gurzov   +7 more
wiley   +1 more source

Successful use of axonal transport for drug delivery by synthetic molecular vehicles

, 2008
We report the use of axonal transport to achieve intraneural drug delivery. We constructed a novel tripartite complex of an axonal transport facilitator conjugated to a linker molecule bearing up to a hundred reversibly attached drug molecules.
Mark Bacon, Miri K. Rabinowitz, John R. Griffiths, Andrew Lever, Alan J. Sokoloff, Aaron G. Filler, Franklyn A. Howe, B. Anthony Bell, Chris Abell, Garth Whiteside, Raj Munglani, Martyn Frederickson, Terrence Deacon   +12 more
core  

Aging Is a Key Driver for Adult Acute Myeloid Leukemia

Aging and Cancer, EarlyView.
Acute myeloid leukemia (AML) is a classical age‐related hematologic malignancy, and a key driver of AML is aging, which profoundly regulates intrinsic factors such as genomic instability, epigenetic reprogramming, and metabolic dysregulation, and alters bone marrow microenvironment.
Rong Yin, Haojian Zhang
wiley   +1 more source

Labeling Regulations and Segregation of First- and, Second-Generation Genetically Modified Products: Innovation Incentives and Welfare Effects, April 2005

, 2005
We review some of the most significant issues and results on the economic effects of genetically modified (GM) product innovation, with emphasis on the question of GM labeling and the need for costly segregation and identity preservation activities ...

core